Many adults come to know the trouble of osteoporosis and/or osteopenia as they grow older. These issues manifest as weakening of a person’s bones due to a significant loss of inorganic bone mass and is commonly associated with great pain and anxiety.
This medicine belongs to the group of bisphosphonates impacting the metabolic processes concerning bones. Its capabilities for the management, as well as preventive procedures of bone loss have been approved by the U.S. Administration for foods and drugs (FDA). However, to date, preventive properties of this medicine have been confirmed only for female patients, whereas males and premenopausal females can benefit exclusively from its therapeutic use. Completely unstudied remains the possibility of using this drug in HIV-positive bone loss disorder sufferers.
Fosamax dose for osteoporosis
Overall, preventive procedures in post-menopausal females requires:
5 mg by mouth once per day or, alternatively, 35 mg by mouth once per week
Dosing schedule for the therapy in males and post-menopausal females is as follows:
10 mg by mouth once per day or, alternatively, 70 mg by mouth once per week
Bone loss caused by glucocorticoids
Both male and female patients: 5 mg by mouth once per day (post-menopausal females who do not stay on HRT should maintain a dose of 10 mg per day)
Fosamax dosage for Paget’s disease
In addition to being applicable in cases of bone loss, Fosamax (Alendronate Sodium) has been used by over 10 million sufferers of Paget’s disease of bone (PDB) since the time of its approval in 1995.
PDB consists in a replacement of strong skeletal elements with disordered bone tissue, which leads to a structural weakness followed by osteomyalgia, bone deformations, cracks, and fractures. In the region of Western Europe, PDB is second only to the bone loss disease in terms of skeletal issue frequency. People from 56 years of age up, including individuals who are genetically susceptible, face a significantly increased risk of PBD development with aging.
Fosamax usual dosage for Paget’s disease:
40 mg/day by mouth for a course of 6 months
The schedule above may remain unadjusted for the cases accompanied by non-severe renal impairment (NMT CrCl 35-60 mL/min).
Related risks and warnings
All bisphosphonates without exceptions may lead to infrequent, but possibly serious, adverse reactions, among which there is maxillary osteonecrosis, and femoral breakages. Hypothetically, this takes place in some long-term users (5 years and more) due to the accumulative effect of osteoclast suppression, which is the reason the bone tissue cannot handle small cracks and becomes brittle.
This drug category is contraindicated in patients with renal failure. Furthermore, certain individuals cannot tolerate alendronate due to gastric and esophageal irritations. In these cases, the physician might consider administering other similar drugs released as injections.
Specifically for Fosamax, missed dose incidences are not dangerous and do not cause problems. Patients should neither make up for the omitted drug amount nor increase the next dose. Misuse and abuse of this medicine are very likely to enhance the risk of adverse events and further withdrawal symptoms.